Teprotumumab

Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research[1].

Product Specifications

CAS Number

[1036734-93-6]

UNSPSC

12352203

Target

IGF-1R; TSH Receptor

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/teprotumumab.html

Purity

99.46

Solubility

10 mM in DMSO

Smiles

[Teprotumumab]

Molecular Weight

(145.671 kDa)

References & Citations

[1]Chen H, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99 (9) :E1635-40.